Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer December 2, 2019December 2, 2019
Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio September 24, 2019October 15, 2019
Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting July 1, 2019October 15, 2019
Amphivena Expands Executive Team – Victoria Smith, Ph.D. Named Chief Scientific Officer; Peter Van Vlasselaer, Ph.D. Appointed Executive Chairman of the Board March 5, 2019October 15, 2019
Amphivena Presents at ASH First-in -Human Phase 1 Clinical Data on AMV564 December 3, 2018October 15, 2019
Amphivena Presents Preclinical Data at ASH that Points to a Potentially New Treatment for MDS Patients December 9, 2017October 15, 2019
Amphivena Receives Orphan Drug Designation for AMV564, a Novel CD33/CD3 T-Cell Engagement Therapy for the Treatment of Acute Myeloid Leukemia November 29, 2017October 15, 2019
Amphivena Announces New Key Leadership and Advisors – Tekla Invests in Series B Round September 11, 2017October 15, 2019
Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation August 10, 2016October 15, 2019
Amphivena Therapeutics to Present Data on Novel Cancer Immunotherapy at 2015 ASCO Annual Meeting May 26, 2015October 15, 2019
Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen April 7, 2015October 15, 2019
